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  ABSTRACT 
The significant relationship between obesity and Type 2 Diabetes has been evidenced 
since ancient times. Ayurveda, Traditional Indian system of medicine, categorizes 
Prameha (diabetes) into two types i.e. Sthula prameha (diabetes in obese people) and 
Krisa prameha (diabetes in lean individuals). The alarming rise in prevalence of these 
disorders without any sign of decline in near future represents a global burden. Several 
prospective studies present impaired insulin release, impaired glucose tolerance, low 
grade inflammation and insulin resistance as the major factors for the development of 
type 2 diabetes. The low grade inflammation that dominates in obesity is the permanent 
elevation of plasma FFA and the predominant utilization of lipids by the muscle 
interfering with the uptake of glucose in skeletal muscle. This review article aims at 
understanding the potential mechanisms that lead human obesity to type 2 diabetes and 
therapeutic interventions for treating these disorders with a focus on the side effects of 
the conventional oral hypoglycemic agents and antiobesity agents. WHO and IDF moving 
with a goal for prevention of this global dual epidemic rather than curing by emphasizing 
the targets in various pathways and weight loss interventions. In this context, the review 
article highlights the potential targets for new therapeutic interventions and significance 
of weight loss for preventing and decreasing the progression of this multifactorial 
disorder.  
KEYWORDS: Adipokines, Diabetes, Diabesity, Incretins, insulin resistance, 
Glucolipotoxicity, obesity. 
INTRODUCTION
The current prevalence of Type 2 Diabetes 
Mellitus (T2DM) and associated obesity 
constitutes a major global health crisis with 
critical complications. The close relationship 
between the diabetes and obesity highlighted by 
term ‘DIABESITY’, coined by Sims and 
colleagues1in 1970’s suggesting a casual 
pathophysiological link between the both 
phenomena. Type 2 diabetes and obesity are 
major health problems that have reached 
epidemic proportions and are growing at alarming 
rates around the world and a drastic increase in 
the population who are managing both the chronic 
diseases. The world health organization (WHO) 
stated the obesity and diabetes as ‘21st century 
epidemic’ 2  referring to joint and parallel increase 




According to International Diabetes 
Federation, the facts and figures represent the 
therapeutic challenge which is grim and shocking. 
According to the IDF diabetic atlas 2012 update 
371 million people are living with diabetes. 
Approximately 63 million people are suffering 
with diabetes in India and china holding the top 
position among the countries with 92.3 million. 
Four out of 5 people are living with diabetes 
among low and middle income countries 3. The 
statistics of IDF state two individuals develop 
diabetes for every 10 sec globally and two 
individuals die of diabetes and its associated 
complications worldwide4. Overweight and 
obesity are the fifth leading risk for global deaths 
causing 2.8 million adults deaths approximately. 
Obesity accounts for 44% of the diabetes burden. 
Global estimates for 2008 are more than 1.4 
billion adults, 20 and older, were overweight. Of 
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these overweight adults, over 200 million men 
and nearly 300 million women were obese. 
Overall, more than one in ten of the world’s adult 
populations were obese 5. Many hypotheses and 
statistics clearly represent a strong defining link 
between the obesity and diabetes. Clinical 
evidence manifest to the relationship between 
being overweight or obese are at an elevated risk 
for development of Type 2 diabetes and adverse 
cardiovascular events. The risk intensifies with 
the degree of excess weight, increasing threefold 
with (BMI) of 25.0-29.9 kg/m2 and 20 fold with a 
BMI over 30kg/m 2. Peculiarly, the increase 
abdominal fat accumulation exacerbates insulin 
resistance and confers a strong, independent link 
for the development of diabetes. The two twin 
epidemics frequently occur together and statistics 
show that 60-90% of all patients with Type 2 
Diabetes mellitus are or have been obese. The 
relative risk for a given obese patient to develop 
T2DM is 10 fold for women and 11.2 fold for men 
7. The Population Attribution Factor (PAF) lay 
down strong defining link to express the 
relationship, and T2DM have a PAF of 88.6% due 
to obesity.  
UNDERSTANDING MOLECULAR LINKS 
BETWEEN OBESITY AND DIABETES 
Many approaches are proposed linking 
obesity to diabetes. The obesity leading to the 
insulin resistance and impaired glucose tolerance 
and May further progresses to the chronic 
condition of T2DM in vulnerable individuals.  
Insulin Deficiency and Insulin Resistance 
The plasma glucose levels are monitored 
and maintained by coordination between 
absorption from intestine, production by liver, 
uptake and metabolism by peripheral tissues. 
Deregulation between these physiological process 
leads to the disturbance of glucose homeostasis 8. 
Insulin plays a key role in coordinating these 
activities by increase glucose uptake in muscle 
and fat, inhibits production of glucose by liver and 
serves as regulator of glucose. The other activities 
mediated by insulin involving in the coordination 
are stimulation of lipogenisis, glycogen and 
proteins, and inhibition of lipolysis. Loss of 
coordination between these factors and processes 
produce elevation in fasting & postprandial 
glucose levels and lipid levels. Defects at many 
levels and alterations in concentration of receptor 
and enzymes involved in cascade of metabolic 
process are characterized in insulin resistance 
states in obesity and diabetes 9. 
Several longitudinal studies revealed that 
people who are genetically predisposed to 
impaired insulin secretion develops diabetes 
when they have acquired obesity induced insulin 
resistance10. T2DM may develop once insulin 
secretion declines at a level at which it cannot 
further indemnify for insulin resistance. Physical 
inactivity, Life style and dietary changes are 
relatively susceptible causes for insulin resistance 
rather than genetic predisposed insulin resistance. 
Insulin sensitivity is negatively correlated with the 
age and body fat of individuals 11. Insulin 
resistance indirectly caused due to increase in 
lipid oxidation and high plasma Free Fatty Acids 
(FFAs) levels in obese non diabetic subjects 9. 
Chronic decrease in glucose oxidation occurs in 
muscle resulting from preferential use of lipids as 
an energy source limiting the use of glucose form 
glycogen stores. In obesity the preferential use of 
FFAs by muscle tissue, resulting in higher 
circulating levels, is a limiting factor for glucose 
oxidation 12. The resistance to glucose uptake in 
obesity after glucose load leads to a greater rise in 
both plasma glucose and insulin concentration. 
This in turn facilitates glucose storage and 
equilibrium is obtained with the compensation for 
resistance to glucose storage by increasing its 
stimulation by elevated glucose and insulin levels. 
The persistent resistance to glucose uptake, in 
spite of the compensatory mechanism of elevated 
glycaemia and insulinemia, gradually leads to type 
2 DM on prolonged obese state of an individual. 
This happens generally when the glucose uptake 
by muscles cannot be regulated in spite of the 
compensatory mechanism of elevated glycaemia 
and insulinemia. Muscles are the major sites for 
insulin resistance, where the chronic disease in 
glucose utilization from glycogen limits the 
further uptake of glucose, which as a consequence, 
remains in the circulation 2. 
Visceral fat and Intra Myocellular Lipids 
(ICML)  
Preferential upper body accumulation of 
fat and increase in fatness are related to insulin 
resistance. Insulin resistance is correlated to 
visceral fat mass independent of body mass index 
(BMI). Visceral fat plays a key role in the 
pathogenesis of insulin resistance. Visceral fat in 
excess has been associated with decrease 
sensitivity of insulin mediated uptake of glucose 
and decreased FFAs re-esterification 13. The 
visceral adipocytes produce FFAs which enter 
portal circulation into liver can induce hepatic 
insulin resistance. The visceral fat was positively 
correlated with the gluconeogenisis flux but was 
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reciprocally associated with glycogenolysis in 
T2DM patients and accumulation of visceral fat 
has a significant negative impact on the circulating 
glucose levels through a decrease in peripheral 
insulin sensitivity and an enhancement of 
gluconeogenisis 14. Recent studies reveal that 
ICML’s exhibit a better correlation factor relating 
to insulin sensitivity rather than circulating 
plasma FFAs 15. H1Nuclear magnetic resonance 
(NMR) studies have shown that ICML’s is a strong 
determinant of in vivo insulin release in humans. 
Drastic weight loss induced by surgical 
procedures like biliopancreatic diversion (BPD) 
decreases 86% ICML’s and normalizes insulin 
sensitivity 16. Good fat oxidation capacity in obese 
patients could help to maintain normal ICML 
concentrations and normalize insulin sensitivity 
thus preventing the ectopic fat accumulation. The 
good ICML’s stored as an adaption to endurance 
training are constantly mobilized for physical 
exercise. On the contrary, the bad lipids stored in 
obese patients are not mobilized and may affect 
insulin sensitivity by the production of lipid 
peroxidation byproducts like 4-HNE and/or 
malondialdehyde 17. 
Free Fatty Acids (FFAs) 
In general plasma FFAs are elevated in 
obese individuals mainly due to increased FA 
release associated with the expansion in fat mass. 
According to Randle hypothesis 18 the insulin 
resistance associated with obesity demonstrated 
by using isolated rat heart muscle and rat 
diaphragm muscle. The underlying mechanism for 
insulin resistance could be the competition 
between increased circulating FFAs and glucose 
for oxidative metabolism in insulin responsive 
cells. The mechanism that they proposed to 
explain the insulin resistance was that elevated 
intramitochondrial acetyl CoA / CoA and NADH/ 
NAD+ ratios and inactivation of pyruvate 
dehydrogenase leading to increased intracellular 
citrate concentrations in turn inhibits 
phosphofructokinase (a key rate controlling 
enzyme in glycolysis). Subsequent accumulation 
of Glucose-6-Phosphate would inhibit hexokinase 
II activity, resulting in an increase in intracellular 
glucose concentrations and decrease glucose 
uptake 19.  
Any disruption that leads to the 
accumulation of intracellular fatty acyl CoA or 
other fatty acid metabolites in the muscle and 
liver, either through increased delivery and/or 
decreased mitochondrial metabolism might be 
underlying cause for insulin resistance. Increase 
intracellular fatty metabolites (diacyl glycerol, 
fatty acyl CoAs, etc) activates serine /threonine 
kinase cascade possibly iniated by protein kinase 
C, IKK-β, c-Jun amino-terminal kinase (JNKs), 
leading to phosphorylation of serine sites on 
insulin receptor substrates. Serine 
phosphorylated forms of these proteins fail to 
associate with and activate PI-3-kinase, resulting 
in decreased activation of glucose transport and 
other downstream events 20. 
Oxidative Stress 
Persistent imbalance between the 
production of highly reactive molecular species 
(chiefly oxygen and nitrogen) and antioxidant 
defenses correlates with fat accumulation in 
humans and mice 22. The oxidative stress is a 
causative factor and plays a key role in 
development of insulin resistance which was 
supported by several studies that showed that 
reversal of imbalance between the ROS (reactive 
oxygen species) and antioxidant improves insulin 
resistance in mice and humans 21. Human studies 
defining link between oxidative stress and insulin 
resistance focus on the generation of ROS by 
hyperglycemia in diabetic patients, implicating 
ROS as a consequence of diabetes induced 
hyperglycemia and not a cause for insulin 
resistance 20. Obesity induced elevations of FFAs 
increase ROS in the prediabetic stage 22. The FFAs 
cause oxidative stress due to increased 
mitochondrial uncoupling and B-oxidation, 
leading to increased production of ROS. In healthy 
subjects, infusion of FAs causes increased 
oxidative stress and insulin resistance that is 
reversed by infusion with antioxidants such as 
glutathione. In vitro, ROS and oxidative stress lead 
to the activation of multiple serine/ threonine 
kinase signaling cascades The activated kinases 
can act on number of potential targets in the 
insulin signaling pathway, including the insulin 
receptor and the family of IRS proteins. When 
concentrations of ROS reach high levels, they can 
cause structural and functional damage to 
proteins, lipids and DNA 23. The recent studies and 
currently favored hypothesis reveal oxidative 
stress as common pathogenic factor leading to 
insulin resistance, β-cell dysfunction and impaired 
glucose tolerance eventually leading to T2DM in 
obese patients 24. Endoplasmic reticulum induces 
Obesity associated insulin resistance by imposing 
strain on ER setup there by activating the JNK and 
impairs the insulin signaling pathway 25. 
LIPO→GLUCOTOXICITY 
The common findings of hyperglycemia 
and hypertriglyceridemia in the blood of diabetic 
patients led to the hypothesis of glucotoxicity 26 
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and lipotoxicity 27. Elevated glucose levels can 
generate excessive levels of ROS. These include 
biochemical pathways like glycolysis, oxidative 
phosphorylation; methylglyoxal formation, 
glycation and sorbital metabolism. β-cells on 
prolonged exposure to high glucose 
concentrations, glucose saturates the normal 
route of glycolysis an increasingly is shunted to 
alternate pathways, such that the ROS are 
generated form distinct metabolic process within 
and outside the mitochondria. Studies indicate 
excess levels of palmitate are associated with 
excessive lipid esterification that, in turn, can 
generate ceramide, thereby increasing oxidative 
stress causing abnormal islet function. It seems 
unlikely, however, that the circulating lipid itself, 
such as triglyceride or cholesterol would be main 
culprits in damaging islet tissue. Glucose might 
lead to lipotoxicity by virtue of its ability to drive 
synthesis of malonyl Coenzyme a, which inhibits 
β-oxidation of free fatty acids. This in turn diverts 
the FFAs towards esterification pathways, there 
by forming triglycerides, ceramides and other 
fatty acid metabolites 26, 28.  
Many physical, pathological and hormonal 
pathways are the causative factors for Insulin 
resistance. Obesity, pregnancy, excess growth 
hormone, glucocorticoid levels and lack of 
exercise are a few that play a significant role in 
developing the insulin resistance. Little evidence 
from research studies also suggests that oxidative 
stress plays a key role in insulin resistance and in 
cellular damage of tissues that lead to 
microvascualr and macrovascular complications 
of diabetes. Abnormal levels of FFAs, TNF-α, leptin 
and resistin prominently found in obese 
individuals mentioned as potential mediators of 
insulin resistance. Free fatty acids have been 
reported to impair insulin action via oxidative 
stress induced activation of NF-κB 21.  
Obesity: Low-grade Inflammatory State 
There is compelling evidence that the 
large component of obesity-associated 
pathophysiology results from a low grade 
proinflammatory state 30. Past decade scientists 
research concerns have come to view obesity as 
low grade inflammatory state. Elevated plasma 
concentrations of circulating mononuclear cells 
and lymphocytes in obese persons, as well the 
adipose tissue and whole body’s increased 
concentration of c-reactive protein(CRP), tumor 
necrosis factor(TNF-α), IL-1, IL-6, MCP-1, PAF-1, 
activation of NF-κB and Jun N-terminal kinase 
systems, are compatible with this considerations 
21. Adipose tissue is considered as the initial site of 
proinflammatory state generation which 
eventually explores the whole body. Visceral fat 
appears to be an active secretor of 
proinflammatory markers more than 
subcutaneous adipose tissue.  
This confirms the crucial role of visceral 
fat in central obesity and in the pathogenesis of 
obesity associated morbidities. The hypothesis 
suggests that the pathogenic mechanism involves 
several heterogeneous factors in the generation of 
state of inflammation within the adipose tissue 
hypoxia, adverse effects of excessive fat storage, 
gut derived pathogen associated molecular 
patterns (PAMPs), infiltration of macrophages and 
increased adipocytes necrosis. The underlying 
metabolic and inflammatory signaling pathways 
impair the insulin effect in the peripheral tissues 
demonstrated linking the obesity related 
proinflammatory state to Insulin Resistance and 
diabetes. Locally within the fat tissue 
inflammation affects the adipocytes which become 
less sensitive to insulin. The resultant suppressed 
pre-adipocytes differentiation and the increased 
NEFA efflux in the systemic circulation increase 
the ectopic fat storage and affect the peripheral 
glucose metabolism 30.  
Influence of Adipokines 
Adipose tissue not only stores 
triglycerides but also it is a major endocrine and 
secretory organ, which release a wide range of 
factors like adipokines, signaling through various 
paracrine and hormonal mechanisms. Adipocytes 
secrete metabolically active proteins which are 
involved in inflammatory process, such as TNF- α, 
IL-1β, IL-6 and MCP-1. Adipokines has a 
significant role in the pathogenesis of obesity 
induced proinflammatory state and insulin 
resistance. The serum concentrations of 
adipokines are altered in the obese individuals, 
where these factors can act as predictors for 
future risk and for early diagnosis of the 
pathogenic states 31.  
Among the various adipocyte secreted 
hormones Leptin was the first adipokine 
discovered by friedman and colleagues in 1994 
influencing the body mass. Its absence correlated 
with dramatic metabolic derangements. The 
discovery of leptin led to correlation between the 
obesity and pathological changes of insulin 
regulating adipokines 32.  
Adiponectin is significant adipokine 
specifically expressed in differentiated adipocytes. 
Its levels are low in obesity. It is relatively highly 
expressed in the systemic circulation than other 
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adipokines. Administration of adiponectin 
improved insulin resistance in animal models and 
mice models deficient of adiponectin developed 
premature diet-induced impairment in glucose 
tolerance insulin resistance, and increased serum 
FFAs. Transgenic mice models with over 
expression of adiponectin lead to improvement in 
insulin sensitivity, glucose tolerance and lower 
serum FFAs. Adiponectin increases insulin 
sensitivity in liver, decreases influx of FFAs and 
increase FA oxidation via activation of AMP-
activated protein kinase(AMPK)33. It regulates 
glucose and lipid metabolism by targeting the liver 
and skeletal muscle through two transmembrane 
receptors AdipoR1 and AdipoR2. While AdipoR1 is 
most abundant in skeletal muscle, AdipoR2 is 
predominantly expressed in liver 34.  
Resistin is an adipocyte-specific secreted 
protein, whose expression is significantly reduced 
by anti-diabetic drugs targeting the nuclear 
receptor Peroxisome Proliferative-Activated 
Receptor γ (PPAR- γ). Its expression and secretion 
pattern differs in humans and rodents. In rodents, 
resistin is predominantly secreted from mature 
adipocytes with weak expression in pancreatic 
islets and hypothalamus. In contrast, humans 
express resistin primarily in macrophages where 
it thought to be involved in secretion of 
proinflammatory factors and recruitment of other 
immune cells Serum resistin levels is elevated in 
rodent obesity and infusion or sustained 
expression of resistin produce insulin resistance. 
Resistin has been shown to induce the expression 
of suppressor of cytokine signaling-3 (SOCS-3), a 
well known negative regulator of insulin signaling 
both in vitro and in vivo 34. But the role of resistin 
is less significant in humans; some of the 
interesting studies in humans reveal consistent 
association between resistin and inflammation. 
 Plasminogen activator inhibitor-1(PAI-1), 
an inflammation associated adipokine belonging 
to serine protease inhibitor family and is primary 
inhibitor of fibrinolysis by inactivating tissue type 
plasminogen activator. Elevated levels of Plasma 
PAI-1are reported in obesity and insulin 
resistance individuals and predict future risk of 
T2DM 35. 
Interleukin IL-6 is a cytokine is closely 
related with obesity and insulin resistance 
Circulating IL-6 concentrations can be positively 
correlated with obesity, impaired glucose 
tolerance and insulin resistance. Plasma IL-6 
predicts the development of T2DM and its 
peripheral administration appears to induce 
hyperlipidemia, hyperglycemia and insulin 
resistance in rodents as well as humans. IL-6 
down regulates IRS and involved in up-regulation 
of SOCS-3 leading to impairment of insulin 
signaling 36.  
Tumor Necrosis Factor α (TNF- α) is the 
first cytokine to be implicated in the pathogenesis 
of obesity and insulin resistance, which is earlier 
described as an endotoxin-induced factor. Adipose 
tissue expression of TNF- α is elevated in obese 
rodents and humans and is being positively 
correlated with adiposity and insulin resistance 
Recent research studies suggest that macrophages 
are the major contributors of TNF- α in adipose 
tissue. Chronic exposure to TNF- α induces insulin 
resistance both in vivo and in vitro. Targeted 
deletion of TNF- α or its receptors significantly 
improves insulin sensitivity and circulating FAs in 
rodent obesity. Potential mechanism for TNFα’s 
metabolic effects have been described, including 
the activation of serine kinases such as JNK and 
P38, Mitogen Activated Protein Kinases(MAPK) 
that increase the serine phosphorylation of IRS-1 
and IRS-2, making them poor substrates for 
insulin receptor-activating kinases and increasing 
their degradation. In humans, circulating TNFα 
level is significantly increased in obese non 
diabetic and T2DM individuals, but the correlation 
between the TNF α and insulin resistance levels 
are relatively weak37, 38.  
Retinol Binding Protein 4(RBP-4) was 
identified as an adipokine, expressed in liver as 
well as adipose tissue whose elevated 
concentrations have been shown to correlate with 
obesity and insulin resistance in rodents. This is 
the most recent adipokine to emerge as 
contributor to obesity induced insulin resistance 
39.  
The entire hypothesis is presented in the form of 
flow chart indicating gradual progression of 
obesity leading to insulin resistance and diabetes. 
11β-HSD1 and its association with obesity  
The other endocrine factors related to the 
obesity and insulin regulation gains the attention 
of glucocorticoid levels. Elevated glucocorticoid 
levels cause insulin resistance and T2DM, 
primarily by opposing the anti-gluconeogenic 
effects of insulin in liver 40. Adipose tissue 
contains 11β-Hydroxysteroid dehydrogenase 
type-1(11β-HSD1), which converts the inactive 
metabolite, cortisone to cortisol in humans and 
11-dehydrocarticosterone to corticosterone in 
rodents. Transgenic overexpression of 11β-HSD1 
selectively in mouse adipose tissue produces a 
syndrome of visceral obesity, insulin resistance 
and diabetes in part due to increase delivery of 
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glucocorticoids to the liver via portal vein 41. 11β-
HSD1 inhibitors could be explored for designing 
therapeutic approaches for glucocorticoid 
suppression and could be promising therapeutic 
agents for treating the metabolic syndrome. 
Indeed, liver-specific antagonism of glucocorticoid 
action reduces hepatic glucose output and 
improves glucose control in animal models of 
obesity-associated insulin resistance. The 
increased delivery of FA and cortisol, as well as 
adipokines, could promote hepatic insulin 
resistance 42.  
THERAPEUTIC OPTIONS  
Antidiabetic Agents  
Many conventional antidiabetic agents 
including the thiazolidinediones (TZDs), insulin, 
meglitinide and sulphonylureas are associated 
with weight gain, an exception for metformin 
which is associated with weight neutrality or 
modest weight reduction 43. The newer basal 
formulation insulin determir exhibits limited 
weight gain in comparison to neutral protamine 
Hagedron (NPH) insulin and detemir. NPH insulin 
and insulin glargine have demonstrated modest 
weight reductions in combination with oral 
antidiabetic drugs in a real world setting 44. 
Conventional antidiabetic treatments include 
insulin; insulin secretagogues and modulators of 
hepatic glucose production (Metformin). 
Metformin, a biguanide commonly recommended 
as initial pharmacotherapy in type2 diabetes, 
inhibits hepatic gluconeogensis and increase 
tissue sensitivity to insulin mediated glucose 
transport 44. Sulphonylureas are glucose 
dependent insulin secretogogues which bind to SU 
receptor on β-cell thereby stimulating the insulin 
release 45. Modulation of PPAR-γ by TZDs 
(Rosiglitazone and Pioglitazone) results in 
transcription of number of genes involved in 
glucose and lipid utilization. This results in 
improved insulin sensitivity of adipose, liver and 
muscle tissue. While each of this classes of agents 
can be effective initially in controlling 
hyperglycemia and lower glycated hemoglobin 
(HbA1c) by 0.5-1.5%, their efficacy progressively 
weakens as insulin resistance increases and β-cell 
function decreases 46. Weight gain, hypoglycemia 
and other treatment-associated adverse effects 
can also demerit the therapeutic benefits of 
antidiabetic agents. In particular weight gain is 
problematic for people with type2 diabetes, as 
even a modest increase in weight can increase 
insulin resistance. Weight gain can be a 
psychological barrier to pharmacotherapy as 
suggested by diabetes Attitudes and wishes, and 
needs study, which found that more than 50% of 
people with T2DM are worried about starting 
insulin therapy because of concern of weight gain 
and 33% of physicians postpone their insulin 
treatment until it is absolutely essential 10. The 
clinical efficacy of rosiglitazone and pioglitazone 
as monotherapy or combination therapy with 
insulin, sulphonylureas or metformin is well 
established 46. Various longitudinal studies 
reported a weight gain of up to 4-5 kg with these 
agents. These agents are also associated with 
edema and risk of congestive heart failure 
exacerbation. Results from RECORD 
(Rosiglitazone Evaluated for cardiac outcomes and 
regulation of glycaemia in diabetes) trial found 
that rosiglitazone, metformin and sulfonylureas 
(its comparators) were associated with similar 
risk for cardiovascular hospitalization rates and 
cardiovascular mortality, but the rosiglitazone 
was associated with significant greater risk of 
heart failure 48. Increase in weight with 
antidiabetic drugs, resulting in a secondary 
increase in insulin resistance, which subsequently 
intensifies the medication requirements to 
maintain glucohomeostasis leading to the patient 
noncompliance. 
Incretins: Newer Oral Antihyperglycemic 
Therapeutic Agents 
The recent clinical studies revealed that 
administration of GLP-1 has shown to normalize 
β-cell sensitivity to glucose and restore first-phase 
insulin response, while suppressing the glucagon 
levels in people with T2DM. It may also have 
extra-glycaemic including satiety induction and 
cardio protection 49. The native GLP-1is rapidly 
degraded and metabolized by the enzyme DPP-4 
enzyme. This hypothesis led to the development of 
new therapeutic interventions, GLP-1 agonist and 
DPP-4 inhibitors for clinical use. GLP-1 receptor 
agonist has different structure from endogenous 
GLP-1, altering their pharmacokinetic properties 
like longer half lives. Exenatide, Exenatide LAR 
(long acting, once week formulation of exenatide), 
Liraglutide are included under this class. These 
agents reduce blood glucose dose-dependently as 
both monotherapy and in combination with other 
agents. They slow gastric emptying and increase 
satiety, mechanisms that are in part responsible 
for weight loss associated with this class. Recent 
studies providing evidence demonstrating that 
treatment with GLP-1 agonist reduce systolic 
blood pressure and triglyceride levels and exert 
beneficial effects on cardiovascular risk factors 50. 
While GLP-1 agonists directly act and stimulate 
the incretin system, DPP-4 inhibitors indirectly 
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enhance the endogenous incretin levels by 
preventing the degradation of endogenous 
incretin levels by preventing the degradation of 
GLP-1 and GIP. Treatment with these agents tends 
to have weight neutral effects which are better 
tolerated in obese T2DM individuals preventing 
weight gain in them. This class of agents includes 
sitagliptin, vildagliptin and saxagliptin.  
These agents tend to have significant 
weight lowering effects on co-administration with 
metformin and no significant effect on weight 
when administered alone 51. Significant reduction 
of glycated hemoglobin (HbA1c) levels was 
observed in T2DM individuals on treating with 
these agents. Concerns rose about long term usage 
of DPP-4 inhibitors on immune function because 
of its expression in lymphocytes 51. The weight 
loss or weight neutrality, seen with various 
incretin agents confers considerable potential 
benefits on cardiovascular parameters in people 
with T2DM. 
Pharmacological and non pharmacological 
strategies to combat obesity  
 Weight loss is of extreme importance in 
Diabesity to limit the development of glucose 
intolerance and progression form impaired 
glucose tolerance to diabetes. Significant effects 
observed with weight loss in the target diabetic 
population was found to have beneficial effects on 
β-cell function. Improved glycaemic control, 
glucotoxicity and lipotoxicity were reversed in the 
individuals with decrease in weight. Weight loss 
may reduce risk factors such as elevated lipid 
levels and blood pressure 52. 
The two primary weight loss interventions are life 
style modifications and pharmacotherapy. 
Life style modifications include regulation 
of diet, regular exercise and behavior changes. The 
pharmacotherapy is used later along with the life 
style modifications. The pharmacotherapy 
includes Sibutramine and Orlistat. These are the 
only two agents currently approved for long term 
use in the treatment of obesity. Orlistat, a 
gastrointestinal lipase inhibitor, reduce weight by 
approximately 3kg on average, improves 
cardiovascular risk factors and decreased 
progression to diabetes in high risk individuals. It 
can be used in individuals with ≥27 with 
comorbidities and in patients with >30 without 
comorbidities. Sibutramine is a monoamine 
reuptake inhibitor with weight loss effects 
associated with increase in satiety. It is associated 
with small increase in blood pressure and pulse 
rate in those who are normotensive, but reduce 
blood pressure in hypertensive. Adverse effects 
include insomnia, nausea and constipation. 
Rimonabant was approved for use in Europe for 
treatment of overweight or obese individuals with 
type2 diabetes. But it is withdrawn for market 
because of its side effects which include 
depression and anxiety. It was first of a new class 
of drugs that acts to suppress appetite by 
selectively inhibiting CB-1, an endocannabinoid 
receptor in adipose tissue and brain 53,54. 
ADIPOKINES: EMERGING THERAPEUTIC 
TARGETS IN DIABESITY 
It is understood that increased production 
of adipokines in obese individuals resulting 
metabolic dysregulation and vascular 
disturbances such as leptin, resistin, and retinol-
binding protein-4. The production of protective 
adipokines, like adiponectin, is reduced causing 
hypoadiponectinemia which appears to play an 
important causal role in insulin resistance, T2DM, 
and the metabolic syndrome. The adiponectin 
receptors, which mediate the antidiabetic actions 
of adiponectin, are down-regulated in obesity-
linked insulin resistance. In addition to its 
protective metabolic effect, adiponectin also has 
beneficial anti-inflammatory and vascular actions. 
Low adiponectin levels have emerged as an 
independent predictor of early atherosclerosis in 
obese patients. Considering all the significant 
effects of adiponectin on the metabolic and 
vascular irregularities, future strategies on 
focusing on up-regulation of expression of 
adiponectin (and/or its receptors) or on targeting 
adiponectin receptors through the development of 
specific agonists represent potential versatile 
targets in patients with Diabesity. 
Another novel peptide system with an 
emerging physiological and pathophysiological 
role in metabolism and cardiovascular 
homeostasis is the apelin/APJ system. Apelin is 
secreted by adipose tissue that influences glucose 
and lipid metabolism as an adipokine through 
binding with a specific G protein-coupled receptor 
(GPCR) named APJ. Apelin treatment appears to 
be effective in obese insulin-resistant mice and 
improves the altered glucose metabolism by 
increasing glucose uptake in skeletal muscle. 
Apelin causes endothelium-dependent 
vasodilatation that appears to be mediated 
predominantly through nitric oxide-dependent 
pathways: in vitro, apelin stimulates transcription 
and phosphorylation of endothelial nitric oxide 
synthase (NOS) and in vivo it increases plasma 
nitrate and nitrite concentrations 55. Overall, given 
the promising preclinical and emerging clinical 
data on the important metabolic and vascular 
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effects of apelin, the potential role of APJ agonism 
in preventing Diabesity and its related vascular 
disease certainly needs exploration in developing 
new therapeutic interventions for Diabesity. 
Di.E.T. and Diabesity 
This acronym Di.E.T. (Dietary 
interventions, Exercise and Treatment) 
introduced by the corresponding author, gives the 
holistic approach towards the management of 
diabesity. Dietary intervention means selection of 
foods and drinks which nourishes the body and in 
turn intervene the disease process. The sequence 
also signifies the acronym i.e. dietary modification 
comes first in the management of Diabesity; 
exercise to mean life style modification and last 
choice is treatment/ management.  
CONCLUSION 
The aim of this review article is to draw 
the attention of clinicians and researchers for the 
urgent and demanding need for novel potential 
candidates for prescription of Diabesity. The 
intention of this article clearly projects the 
necessity of potential therapeutic agents in obese 
T2DM individuals and weight gain due to 
conventional antidiabetic agents. Exploration of 
complementary and alternative medicine in this 
area might provide a solution for this 
multidimensional pathogenesis. Given the current 
global scenario of T2DM and obesity, the evidence 
of this pathogenic interrelationship constitutes a 
major global health problem. The ongoing 
worldwide epidemic of Diabesity being a disaster 
itself, it strikingly increases the risk of possible 
comorbidities. The pathological mechanisms 
underlying the Diabesity needed to be explored to 
identify the potential pharmacological targets for 
prevention of this multifactroial and pathogenic 
complex disorder in order to alleviate the human 
suffering. The effective weight loss interventions 
(life style and pharmacotherapy) must be 
incorporated in daily life as soon as the diabetes is 
diagnosed. Effective pharmacotherapy along with 
the life style modification might provide a 
significant relief to this unmet medical need.  
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